Cardiovascular safety in patients receiving roflumilast for the treatment of COPD

Chest

Volumn 144, Issue 3, 2013, Pages 758-765

  White, William B ^a   Cooke, Glen E ^b   Kowey, Peter R ^c   Calverley, Peter M A ^d   Bredenbröker, Dirk ^e   Goehring, Udo Michael ^e   Zhu, Haiyuan ^f   Lakkis, Hassan ^f   Mosberg, Hans ^e   Rowe, Paul ^f   Rabe, Klaus F ^g  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^e Respiratory Medicine   (Switzerland)

^f FOREST RESEARCH INSTITUTE   (United States)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LONG ACTING DRUG; PLACEBO; RENIN INHIBITOR; ROFLUMILAST; SALMETEROL; SHORT ACTING DRUG; TIOTROPIUM BROMIDE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

EID: 84884305030     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-2332     Document Type: Article

References (31)

1. Rabe KF, Hurd S, Anzueto A, et al ; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007 ; 176 (6): 532-555.
2. Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010 ; 65 (11): 956-962.
3. Hawkins NM, Huang Z, Pieper KS, et al ; Valsartan in Acute Myocardial Infarction Trial Investigators. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail. 2009 ; 11 (3): 292-298.
4. Salisbury AC, Reid KJ, Spertus JA. Impact of chronic obstructive pulmonary disease on post-myocardial infarction outcomes. Am J Cardiol. 2007 ; 99 (5): 636-641.
5. Burgel PR, Paillasseur JL, Peene B, et al. Two distinct chronic obstructive pulmonary disease (COPD) phenotypes are asso ciated with high risk of mortality. PLoS ONE. 2012; 7(12): e51048.
6. Fabbri LM, Rabe KF. From COPD to chronic systemic infl ammatory syndrome? Lancet. 2007 ; 370 (9589): 797-799.
7. Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor rofl umilast in patients with COPD. Thorax. 2007 ; 62 (12): 1081-1087.
8. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ ; M2-124 and M2-125 study groups. Rofl umilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009; 374(9691): 685-694.
9. White WB, Faich G, Borer JS, Makuch RW. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol. 2003 ; 92 (4): 411-418.
10. Sidney S, Sorel M, Quesenberry CP Jr, DeLuise C, Lanes S, Eisner MD. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest. 2005 ; 128 (4): 2068-2075.
11. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic infl ammation in chronic obstructive pulmonary disease. Circulation. 2003; 107(11): 1514-1519.
12. Tashkin DP, Celli B, Senn S, et al; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008 ; 359 (15): 1543-1554.
13. Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest. 2006 ; 130 (6): 1695-1703.
14. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med. 2005 ; 143 (5): 317-326.
15. Rennard SI. Clinical approach to patients with chronic obstructive pulmonary disease and cardiovascular disease. Proc Am Thorac Soc. 2005 ; 2 (1): 94-100.
16. Takabatake N, Nakamura H, Abe S, et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000; 161(4 pt 1): 1179-1184.
17. Eid AA, Ionescu AA, Nixon LS, et al. Infl ammatory response and body composition in chronic obstructive pulmo nary disease. Am J Respir Crit Care Med. 2001; 164(8 pt 1): 1414-1418.
18. Schols AM, Buurman WA, Staal van den Brekel AJ, Dentener MA, Wouters EF. Evidence for a relation between metabolic derangements and increased levels of infl ammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax. 1996 ; 51 (8): 819-824.
19. Hatzelmann A, Schudt C. Anti-infl ammatory and immunomodulatory potential of the novel PDE4 inhibitor rofl umilast in vitro. J Pharmacol Exp Ther. 2001 ; 297 (1): 267-279.
20. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R. In vivo effi cacy in airway disease models of rofl umilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther. 2001 ; 297 (1): 280-290.
21. Rodrigo GJ, Castro-Rodriguez JA, Plaza V. Safety and effi cacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review. Chest. 2009 ; 136 (4): 1029-1038.
22. Calverley PM, Anderson JA, Celli B, et al ; TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results. Thorax. 2010 ; 65 (8): 719-725.
23. Calverley PM, Anderson JA, Celli B, et al ; TORCH investigators. Salmeterol and fl uticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007 ; 356 (8): 775-789.
24. Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP. Cardiovascular safety of tiotropium in patients with COPD. Chest. 2010 ; 137 (1): 20-30.
25. Bredenbröker D, Syed J, Leichtl S, Rothgeb F, Wurst W. Safety of once-daily rofl umilast, a new, orally active, selective phosphodiesterase 4 inhibitor, in patients with COPD [abstract]. Am J Respir Crit Care Med. 2002 ; 165 (595 pt 2): A595.
26. Bredenbröker D, Syed J, Leichtl S, Rathgeb F, Wurst W. Rofl umilast, a new orally active phosphodiesterase 4 inhibitor, is effective in the treatment of chronic obstructive pulmonary disease [abstract]. Eur Respir J. 2002 ; 20 (suppl 38): 374s.
27. Boszormenyi-Nagy G, Pieters WR, Steffen H, et al. The effect of rofl umilast treatment and subsequent withdrawal in patients with COPD [abstract]. Proc Am Thorac Soc. 2005 ; 2 (abstracts issue): A544.
28. Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbröker D, Bethke TD. Rofl umilast-an oral anti-infl ammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2005 ; 366 (9485): 563-571.
29. Rennard SI, Calverley PM, Goehring UM, Bredenbröker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor rofl umilast-the importance of defi ning different subsets of patients with COPD. Respir Res. 2011 ; 12 : 18.
30. Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-year treatment with rofl umilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007 ; 176 (2): 154-161.
31. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al; M2-127 and M2-128 Study Groups. Rofl umilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009; 374 (9691): 695-703.